This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Malignant Neoplasm of Corpus Uteri, C54자궁체부의 악성신생물 (자궁체부암)

Special Copayment Reduction V193 — a copayment of 5% of covered medical care costs applies for 5 years from the date of cancer patient registration (the Cancer Control Act and National Health Insurance special copayment reduction regulations)
Adult onset: very high | ICD-10: C54 (including endometrial cancer C54.1)
Contents (Table of Contents)
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

Corpus uteri cancer, particularly endometrial carcinoma, is a malignant epithelial tumor arising from the endometrium. The clinical history of endometrial cancer began to be described in earnest from the early 20th century. With the introduction of endometrial curettage (D&C) as a diagnostic method in the early 1900s, histological diagnosis of endometrial lesions became possible.

In 1947, Gertrude Diering and colleagues first proposed a relationship between endometrial cancer and estrogen exposure, and in 1975 Ziel and Finkle published an epidemiological study showing that unopposed estrogen exposure increases the risk of endometrial cancer about 5–8 times, establishing the etiological concept of type I (estrogen-dependent) endometrial cancer. This led to the switch from estrogen-only therapy (ERT) to combined hormone therapy with added progestin as the standard.

In 1983, Bokhman proposed the concept of dividing endometrial cancer into type I (estrogen-dependent, endometrioid histology, favorable prognosis) and type II (non-estrogen-dependent, serous/clear cell type, poor prognosis). This dichotomous system was used as the framework for clinical practice and research for decades.

In 2013, The Cancer Genome Atlas (TCGA) research consortium identified four molecular subtypes (POLE ultramutated, MSI-H/dMMR, NSMP, p53-abnormal) through comprehensive genomic analysis of endometrial cancer. This classification proved superior to the previous histological dichotomy for predicting prognosis, and in 2023 FIGO made the historic shift of integrating molecular classification into its revised staging system (FIGO 2023m). The 2023 FIGO staging system recommends recording the POLEmut, MMRd, NSMP, and p53abn molecular subtypes together with the anatomical stage.

In terms of treatment, the GOG-99 trial in 1988 established the role of postoperative radiation therapy, and in 2019 PORTEC-3 reported the superiority of combined chemoradiotherapy in advanced endometrial cancer. In 2022, KEYNOTE-775 (Study 309) demonstrated a survival benefit of lenvatinib + pembrolizumab over chemotherapy in recurrent endometrial cancer and received US FDA approval. In Korea, the incidence of endometrial cancer has shown a steep trend, more than tripling from an ASR of 2.38 in 1999 to 7.29 in 2018, along with Westernized dietary patterns and rising obesity prevalence.

2. Causes

The causes of endometrial cancer differ according to two etiological types.

Risk factors for type I endometrial cancer (estrogen-dependent)

Causes of type II endometrial cancer (non-estrogen-dependent)

This includes serous endometrial cancer (serous EEC), clear cell carcinoma, carcinosarcoma, and others, and its relationship with estrogen is unclear. It is associated with TP53 mutations, HER2 amplification, and the p53abn molecular subtype. Occurrence at an older age and after menopause is characteristic.

Hereditary risk factors

Lynch syndrome (hereditary nonpolyposis colorectal cancer): caused by germline mutations of DNA mismatch repair (MMR) genes such as MLH1, MSH2, MSH6, and PMS2, and endometrial cancer is the most common gynecologic cancer in patients with Lynch syndrome. The lifetime risk of endometrial cancer in women with Lynch syndrome is about 25–60%. The risk of endometrial cancer is also high in PTEN hamartoma tumor syndrome (Cowden syndrome).

3. Genetics

The TCGA (2013) genomic analysis of endometrial cancer identified 4 molecular subtypes, which were integrated into the 2023 FIGO staging system.

FIGO 2023 molecular subtypes

Molecular subtypeCharacteristicsPrognosisProportion (%)
POLEmut (POLE ultramutated)Pathogenic mutation in the POLE proofreading domain, ultramutation (thousands of mut/Mb), MSSVery favorable (5-year OS ~100%)~5~7%
MMRd (dMMR/MSI-H)MLH1 promoter methylation or MMR gene mutation, MSI-HFavorable to intermediate~25~30%
NSMP (No Specific Molecular Profile)POLE wild-type, MSS, p53 wild-type. Mainly endometrioid histology. Frequent CTNNB1 mutationsModerate~50%
p53abn (p53-abnormal)Pathogenic TP53 mutation, complex chromosomal abnormalities, mainly serous/clear cell/high-gradePoor~15~20%

Major somatic mutations

Lynch syndrome-related MMR

Germline MMR gene mutations (MLH1, MSH2, MSH6, PMS2) are tested in endometrial cancer by immunohistochemistry (IHC) or MSI PCR. ASCO and ESGO guidelines recommend performing MMR testing (universal screening) in all patients with endometrial cancer.

4. General epidemiology

Uterine corpus cancer (mostly endometrial cancer) is the fastest-increasing gynecologic cancer in Korea. Westernized dietary patterns, rising obesity prevalence, and a declining birth rate are cited as the main causes.

Global situation

Endometrial cancer is the most common gynecologic cancer in developed countries, with about 417,000 new diagnoses annually worldwide. Incidence is high in Western Europe and North America and is also rising sharply in East Asia.

Situation in Korea

In Korea, the age-standardized incidence rate (ASR) of endometrial cancer more than tripled from 2.38 per 100,000 in 1999 to 7.29 per 100,000 in 2018. It rose sharply from 5.6 per 100,000 in 2010 to 8.8 per 100,000 in 2019 and ranks 7th among malignant tumors in women. The overall 5-year survival rate is reported to be about 84.4% (by histologic type: endometrioid 90.9%, serous 55.0%, clear cell 68.5%). The median age at diagnosis is about 55–60 years, and occurrence around menopause is also increasing.

CategoryFigureNotes
Korean ASR (1999)2.38 per 100,000 womenKCCR data
Korean ASR (2018)7.29 per 100,000 womenMore than 3-fold increase
Korean 5-year survival rate (endometrioid type)90.9%KCCR-based follow-up
Korean 5-year survival rate (serous)55.0%High-risk histologic type
New diagnoses worldwide (2020)About 417,000Most common gynecologic cancer (developed countries)
Median age at diagnosis (Korea)55–60 yearsIncreasing occurrence around menopause

5. Pathophysiology

Pathogenesis of type I endometrial cancer (estrogen-dependent)

When estrogen binds to the estrogen receptor (ER) of endometrial cells, transcription of genes related to cell proliferation (MYC, CCND1, EGFR, etc.) is activated. Sustained estrogen stimulation in the absence of progestin causes multistep progression from endometrial hyperplasia → atypical endometrial hyperplasia (AEH) → type I endometrial cancer. PTEN deletion appears as an early change, after which PIK3CA mutations, KRAS mutations, CTNNB1 mutations, and MMR defects accumulate sequentially.

In obesity, androstenedione is converted to estrone (E1) by aromatase in adipocytes, increasing circulating estrogen. Obesity also raises free estrogen concentrations by decreasing SHBG (sex hormone-binding globulin) and promotes endometrial cell proliferation via the insulin-IGF-1 pathway. Leptin excess and adiponectin deficiency also contribute to endometrial malignant transformation.

Pathogenesis of type II endometrial cancer (non-estrogen-dependent)

It begins as serous endometrial intraepithelial carcinoma (sEIC) and progresses to invasive serous endometrial cancer. TP53 mutation is the key early event, after which PIK3CA mutations, FBXW7 mutations, HER2 amplification, and others are added. These tumors tend to arise against a background of endometrial atrophy. Complex chromosomal abnormalities (CNV-high) are characteristic, corresponding to the p53abn subtype of the TCGA classification.

POLE ultramutation pathway

Pathogenic mutations of the POLE gene (the proofreading domain of DNA polymerase ε) abolish the proofreading function during DNA replication, causing ultramutation (hundreds to thousands of mut/Mb). This maximizes the generation of immunogenic neoantigens, inducing a strong intratumoral immune response, and as a result it has the best prognosis (5-year OS ~100%). Paradoxically, POLE mutations have a very favorable prognosis even when they show high-grade morphological findings (high-grade endometrioid carcinoma, FIGO grade 3).

6. Symptoms

The most important symptom of uterine corpus cancer is abnormal uterine bleeding, which is the key clue to early detection.

Main symptoms

7. Signs

Physical examination findings

Gynecologic examination findings

8. Screening

There is currently no recognized screening program for endometrial cancer in the general population. This is because endometrial cancer has a distinct early symptom (abnormal bleeding), so symptom-based diagnosis is relatively effective.

Surveillance of high-risk groups

Transvaginal ultrasound (TVS)

In postmenopausal women, an endometrial thickness of ≥4–5 mm is an indication for endometrial evaluation. However, the normal endometrial thickness threshold differs depending on whether hormone therapy is used. Transvaginal ultrasound is used as a diagnostic aid rather than a screening tool.

9. Diagnosis

Endometrial tissue sampling

Imaging

FIGO 2023 staging (molecular integration)

StageDefinitionEffect of molecular subtype
IAConfined to the endometrium or myometrial invasion <50%; histological grade 1–2POLEmut → may be downstaged
IBMyometrial invasion <50%; histological grade 3 / myometrial invasion ≥50%; grade 1–3p53abn → may be upstaged
IICervical stromal invasionp53abn IB → IIA; POLEmut II → downstaged
IIILocal extrauterine involvement (ovary, vagina, peritoneum, lymph nodes)Detailed adjustment by molecular subtype
IVAInvasion of the bladder/rectal mucosa—
IVBDistant metastasis—

Molecular classification tests

10. Treatment

Surgical treatment (basic)

Total laparoscopic (or robot-assisted) hysterectomy + bilateral salpingo-oophorectomy + pelvic lymph node sampling or dissection is standard. Para-aortic lymph node sampling is added when high-risk factors are present. Sentinel lymph node biopsy (SLN mapping) is gradually becoming standard as an alternative to lymphadenectomy in early endometrial cancer (radioactive tracer + ICG fluorescence).

Postoperative adjuvant therapy

Adjuvant treatment is individualized according to molecular subtype and recurrence risk group.

Treatment of recurrent/metastatic endometrial cancer

11. Prognosis

5-year survival rate by stage

FIGO stage5-year survival
Stage I80~95%
Stage II70~80%
Stage III40~60%
Stage IV15~25%

Prognosis by molecular subtype (5-year OS)

Poor prognostic factors

12. Prevention

Management of obesity and metabolic diseases

The most important prevention strategy for endometrial cancer is preventing obesity. Weight control, regular physical activity, and a healthy dietary pattern (more vegetables and fruits, less refined carbohydrate and saturated fat) lower the risk of endometrial cancer. Effectively managing diabetes and insulin resistance also helps prevention.

Oral contraceptive use

Use of combined oral contraceptives (estrogen-progestin combination) reduces the risk of endometrial cancer by about 30–50%, and the protective effect increases with longer duration of use. The protective effect persists for several years after stopping.

Management of hereditary high-risk groups

In women with Lynch syndrome, prophylactic hysterectomy + bilateral salpingo-oophorectomy is strongly recommended at age 35–40 or after completion of childbearing. Until prophylactic surgery, annual surveillance with endometrial tissue biopsy is recommended.

Appropriate use of hormone therapy

When postmenopausal hormone therapy is needed, progestin is combined to prevent unopposed estrogen stimulation. If abnormal vaginal bleeding occurs during tamoxifen use, immediate endometrial evaluation is performed.

Parity

Oral contraceptives or childbirth (maintaining parity) lower the risk of developing endometrial cancer.

13. References

  1. FIGO Staging of Endometrial Cancer: 2023. J Gynecol Oncol. 2023;34:e85. ejgo.org
  2. 2023 FIGO Staging with Molecular Classification: Dawn and Challenges. PMC12664729. 2025.
  3. TCGA. Integrated Genomic Characterization of Endometrial Carcinoma. Nature. 2013;497(7447):67-73.
  4. Trends in the Incidence and Survival Outcomes of Endometrial Cancer in Korea. J Gynecol Oncol. 2024;35:e32.
  5. Eskander RN, et al. Pembrolizumab plus Chemotherapy for Advanced Endometrial Cancer. KEYNOTE-868/NRG-GY018. N Engl J Med. 2023;388(23):2159-2170.
  6. Mirza MR, et al. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer (RUBY). N Engl J Med. 2023;388(23):2145-2158.
  7. Makker V, et al. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer (KEYNOTE-775). N Engl J Med. 2022;386(5):437-448.
  8. Real-world Experience of Pembrolizumab and Lenvatinib in Korea. PubMed 35277278. 2022.
  9. Molecular Classification and 2023 FIGO Staging: Exploring Challenges for Pathologists. PMC10452831. 2023.
  10. Cancer Statistics in Korea 2023. PMC13093029. 2026.
  11. de Boer SM, et al. PORTEC-3: Adjuvant Chemoradiotherapy versus Radiotherapy for Advanced Endometrial Cancer. Lancet Oncol. 2018;19(3):295-309.